Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Campagna, A. C.
Right arrow Articles by Golden, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Campagna, A. C.
Right arrow Articles by Golden, J. A.

Chest, Vol 101, 1274-1281, Copyright © 1992 by American College of Chest Physicians

ARTICLES

Pulmonary manifestations of the eosinophilia-myalgia syndrome associated with tryptophan ingestion

AC Campagna, PD Blanc, LA Criswell, D Clarke, KE Sack, WM Gold and JA Golden
University of California, San Francisco, Division of Pulmonary and Critical Care Medicine.

Pulmonary manifestations are not infrequent in the L-tryptophan-induced eosinophilia-myalgia syndrome (EMS). However, previous reports have not described the results of longitudinal pulmonary function, exercise testing, high-resolution computerized tomographic (HRCT) scanning of the chest, or detailed bronchoalveolar lavage (BAL) analysis. We report six patients with EMS who had dyspnea. The diffusing capacity for carbon monoxide was decreased in five patients tested. Exercise testing with arterial blood gas sampling in three patients was consistent with pulmonary vascular or parenchymal disease. Serial exercise testing in two of these patients demonstrated marked improvement temporally associated with corticosteroid treatment. In four patients, HRCT scanning of the chest was abnormal. One of these patients showed no abnormality on routine chest roentgenogram. Two patients undergoing BAL exhibited increased eosinophils in the lavage fluid; a third had elevated lymphocytes. Serial measurements of fibroblast proliferation- stimulating-activity in samples of BAL fluid obtained from serial examinations in two patients exhibited heightened pretreatment activity that returned to the normal range following corticosteroid therapy. In these two patients, increased proportions of T-suppressor/cytolytic (CD8+) cells were observed in the BAL fluid. Despite aggressive immunosuppressive therapy, one of the patients died of respiratory failure. Another remains markedly dyspneic with pulmonary hypertension. Of the remaining four patients, two exhibited resolution of pulmonary symptoms after systemic corticosteroid therapy, and two experienced partial improvement.


This article has been cited by other articles:


Home page
 ChestHome page
S. Harari, R. Cassandro, J. Chiodini, A. M. Taveira-DaSilva, and J. Moss
Effect of a Gonadotrophin-Releasing Hormone Analogue on Lung Function in Lymphangioleiomyomatosis
Chest, February 1, 2008; 133(2): 448 - 454.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
G. Passalacqua and C. Lombardi
Iatrogenic Eosinophilia--Reply
Arch Intern Med, January 12, 2004; 164(1): 106 - 106.
[Full Text] [PDF]

Home page
 NEJMHome page
R. L. Kradin and E. J. Mark
Case 1-1993- A Seven-Year-Old Girl with Recurrent Bouts of Sore Throat, Cough, Dyspnea, and Fever
N. Engl. J. Med., January 7, 1993; 328(1): 48 - 55.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1992 by the American College of Chest Physicians.